COVID-19 Patient and Family Survey – Phase 2

Other News // 28th August 2020

How has COVID-19 affected your myeloma treatment and care?

What is life like now shielding has been lifted?

Has COVID-19 affected your work and income?

In June more than 1,100 of you responded to our survey on the impact of COVID-19. The survey results represent the single most comprehensive and detailed picture of life in the UK during COVID-19 for myeloma patients and their family and friends.

Today are we launching a second survey so that we can learn more about how COVID-19 is impacting on people affected by myeloma as the situation changes and develops. Speaking about the launch of the second survey, Director of Research and Patient Advocacy, Sarah McDonald said:

“The response to our first survey was fantastic and we want to say a huge thank you to everyone who took part.

“We have been able to share the unique insight it gave us with decision makers in the NHS and Government, and with MPs and members of the devolved assemblies and use it to call for the treatment and care you need.

“For example, your survey answers supported our call that the NHS should make alternative myeloma treatments available as long as they were needed. Now NHS England have confirmed they will be in place until the end of March next year, helping to make sure that patients can continue to be treated if attending hospital is difficult because of COVID-19.

“As we know, unfortunately COVID -19 is still with us and we are determined to keep the focus on myeloma patients and their friends and families in the coming months.

“This second survey will give us an up to the minute picture and will gather more evidence on the impact on myeloma treatment and care, on practical issues now that shielding has paused and how you are coping with work and family life.

“You can help us make your voice heard with the people who matter by filling in the survey and sharing it with others. We hope you will.”

The survey can be accessed here. If you have any further queries regarding the survey please contact us at: